Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors

Clinical Rheumatology

Volumn 29, Issue 11, 2010, Pages 1301-1309

  Pedersen, Susanne Juhl ^a   Hetland, Merete Lund ^b,c   Sørensen, Inge Juul ^b   Østergaard, Mikkel ^b   Nielsen, Hans Jørgen ^b   Johansen, Julia Sidenius ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c Danish Rheumatologic Database (DANBIO)   (Denmark)

Author keywords

Biomarkers; Interleukin 6; Long term changes; Matrix metalloproteinase 3; Spondyloarthritis; TNF inhibitors; Total aggrecan; Vascular endothelial growth factor; YKL 40

Indexed keywords

ADALIMUMAB; AGGRECAN; BIOLOGICAL MARKER; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 6; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; YKL 40;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; COMORBIDITY; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SPONDYLARTHRITIS; TREATMENT RESPONSE;

ADULT; AGED; AGGRECANS; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HUMANS; INTERLEUKIN-6; LECTINS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; SPONDYLARTHRITIS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77957704560     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1528-x     Document Type: Article

References (25)

1. DD Gladman C Antoni P Mease DO Clegg P Nash 2005 Psoriatic arthritis: epidemiology, clinical features, course, and outcome Ann Rheum Dis 64 ii14 ii17 10.1136/ard.2004.032482 15708927
2. J Sieper J Braun M Rudwaleit A Boonen A Zink 2002 Ankylosing spondylitis: an overview Ann Rheum Dis 61 iii8 iii18 12381506
3. EU Sumer BC Sondergaard JC Rousseau PD Delmas AJ Fosang MA Karsdal, et al. 2007 MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays Osteoarthritis Cartilage 15 212 221 1:STN:280:DC%2BD2s%2FltF2ksg%3D%3D 10.1016/j.joca.2006.07.009 16997584
4. WP Maksymowych 2009 What do biomarkers tell us about the pathogenesis of ankylosing spondylitis? Arthritis Res Ther 11 101 10.1186/ar2565 19183433
5. ML Hetland HM Lindegaard A Hansen J Podenphant J Unkerskov VS Ringsdal, et al. 2008 Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry Ann Rheum Dis 67 1023 1026 1:STN:280:DC%2BD1czot1yitw%3D%3D 10.1136/ard.2007.087262 18272669
6. OB Pedersen GO Hansen AJ Svendsen L Ejstrup P Junker 2007 Adaptation of the Bath measures on disease activity and function in ankylosing spondylitis into Danish Scand J Rheumatol 36 22 27 1:STN:280:DC%2BD2s3ksFKlug%3D%3D 10.1080/03009740600904268 17454931
7. J Braun J Sieper 2002 Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 January 2002 Ann Rheum Dis 61 iii61 iii67 12381512
8. J Braun T Pham J Sieper J Davis S van der Linden M Dougados, et al. 2003 International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis Ann Rheum Dis 62 817 824 1:CAS:528:DC%2BD3sXns1SisLg%3D 10.1136/ard.62.9.817 12922952
9. T Pham F Guillemin P Claudepierre M Luc C Miceli-Richard B Fautrel, et al. 2006 TNFalpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology Joint Bone Spine 73 547 553 1:CAS:528:DC%2BD28Xht1Sqs7zN 10.1016/j.jbspin.2006.02.005 16843030
10. WP Maksymowych GS Jhangri RG Lambert C Mallon H Buenviaje E Pedrycz, et al. 2002 Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety J Rheumatol 29 959 965 1:CAS:528:DC%2BD38XktlShs70%3D 12022358
11. B Vandooren E Kruithof DT Yu M Rihl J Gu L De Rycke, et al. 2004 Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy Arthritis Rheum 50 2942 2953 1:CAS:528:DC%2BD2cXoslGgsbw%3D 10.1002/art.20477 15457463
12. S Visvanathan C Wagner JC Marini D Baker T Gathany J Han, et al. 2008 Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab Ann Rheum Dis 67 511 517 1:CAS:528:DC%2BD1cXltlSksrw%3D 10.1136/ard.2007.071605 17644552
13. E Kruithof L De Rycke J Roth H Mielants F Van den Bosch F De Keyser, et al. 2005 Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies Arthritis Rheum 52 3898 3909 1:CAS:528: DC%2BD28XjvF2hsg%3D%3D 10.1002/art.21426 16329106
14. WP Maksymowych AR Poole L Hiebert A Webb M Ionescu T Lobanok, et al. 2005 Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis J Rheumatol 32 1911 1917 1:CAS:528:DC%2BD2MXhtFOqt7bM 16206346
15. H Appel L Janssen J Listing R Heydrich M Rudwaleit J Sieper 2008 Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment Arthritis Res Ther 10 R125 10.1186/ar2537 18945353
16. WP Maksymowych P Rahman K Shojania WP Olszynski GT Thomson S Ballal, et al. 2008 Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis J Rheumatol 35 2030 2037 1:CAS:528:DC%2BD1cXhtlWit7bJ 18785308
17. J Braun A Deodhar B Dijkmans P Geusens J Sieper P Williamson, et al. 2008 Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period Arthritis Rheum 59 1270 1278 1:CAS:528:DC%2BD1cXhtlKqsbzO 10.1002/art.24001 18759257
18. B Dijkmans P Emery M Hakala M Leirisalo-Repo EM Mola L Paolozzi, et al. 2009 Etanercept in the longterm treatment of patients with ankylosing spondylitis J Rheumatol 36 1256 1264 1:CAS:528:DC%2BD1MXotlSjtLw%3D 10.3899/jrheum.081033 19411393
19. D Van Der Heijde MH Schiff J Sieper A Kivitz RL Wong H Kupper, et al. 2008 Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial Ann Rheum Dis 68 922 929 10.1136/ard.2007.087270 18701556
20. CE Antoni A Kavanaugh D Van Der Heijde A Beutler G Keenan B Zhou, et al. 2008 Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) J Rheumatol 35 869 876 1:CAS:528: DC%2BD1cXntVOmurY%3D 18381786
21. PJ Mease P Ory JT Sharp CT Ritchlin F Van Den Bosch F Wellborne, et al. 2009 Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) Ann Rheum Dis 68 702 709 1:CAS:528:DC%2BD1MXls1Chu78%3D 10.1136/ard.2008.092767 18684743
22. K Briot C Roux L Gossec N Charni S Kolta M Dougados, et al. 2008 Effects of etanercept on serum biochemical markers of cartilage metabolism in patients with spondyloarthropathy J Rheumatol 35 310 314 1:CAS:528:DC%2BD1cXjtFamtrY%3D 18203315
23. JC Davis Jr DM van der Heijde M Dougados J Braun JJ Cush DO Clegg, et al. 2005 Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept J Rheumatol 32 1751 1754 1:CAS:528:DC%2BD2MXhtFSktb7I 16142873
24. M Rudwaleit S Schwarzlose ES Hilgert J Listing J Braun J Sieper 2008 MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis Ann Rheum Dis 67 1276 1281 1:STN:280: DC%2BD1crhtlWjtA%3D%3D 10.1136/ard.2007.073098 18006539
25. M Rudwaleit P Claudepierre P Wordsworth EL Cortina J Sieper M Kron, et al. 2009 Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis J Rheumatol 36 801 808 1:CAS:528:DC%2BD1MXkvFemtLw%3D 10.3899/jrheum.081048 19273449